

(+34 C

LABORATORIO

APPENDIX I

GENERAL		
2nd HALF-YEARLY FINANCIAL REPORT FOR THE REPORTING P	PERIOD 202	24
PERIOD END DATE 31/12/2024		_
I. IDENTIFICATION DETAILS		
O		
Corporate name: LABORATORIOS FARMACEUTICOS ROVI, S.A.		
Registered address: c/ Julián Camarillo, 35, 28037 Madrid	Tax Id No. A-28041283	
II. INFORMATION SUPPLEMENTING THE PERIODIC INFORMATION PUBLI	SHED PREVIOUSL	Υ



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

1. INDIVIDUAL STATEMENT OF FINANCIAL POSITION (PREPARED USING NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

ASSETS		CURRENT PERIOD 31/12/2024	PREVIOUS PERIOD 31/12/2023
A) NON-CURRENT ASSETS	0040	180.316	161.972
1. Intangible assets:	0030	26.674	27.248
a) Goodwill	0031		
b) Other intangible assets	0032	26.674	27.248
2. Property, plant and equipment	0033	44.256	47.071
3. Investment property	0034		
4. Non-current investments in group and associated companies	0035	106.553	84.982
5. Non-current financial investments	0036	1.588	1.436
6. Deferred tax assets	0037	1.245	1.235
7. Other non-current assets	0038		
B) CURRENT ASSETS	0085	306.493	302.406
Non-current assets held for sale	0050		
2. Inventories	0055	130.097	119.569
3. Trade and other receivables	0060	112.829	119.411
a) Trade receivables for sales of goods and services	0061	108.914	114.411
b) Other receivables	0062	3.915	5.000
c) Current tax assets	0063		
4. Current investments in group and associated companies	0064	44.948	48.842
5. Current financial investments	0070		
6. Current accruals and prepayments	0071	2.062	1.561
7. Cash and cash equivalents	0072	16.557	13.023
TOTAL ASSETS (A+B)	0100	486.809	464.378



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

1. INDIVIDUAL FINANCIAL STATEMENTS (PREPARED USING THE NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

LIABILITIES AND EQUITY	CURRENT PERIOD 31/12/2024	PREVIOUS PERIOD 31/12/2023	
A) EQUITY (A.1 + A.2 + A.3)	0195	60.284	89.322
A.1) EQUITY	0180	59.283	87.975
1. Capital:	0171	3.074	3.241
a) Authorized capital	0161	3.074	3.241
a) Less: uncalled capital	0162		
2. Share premium	0172	87.636	87.636
3. Reserves	0173	7.032	7.032
4. Less: treasury stock	0174	(5.545)	(107.676)
5. Retained earnings	0178	(108.460)	85.671
6. Other shareholder contributions	0179		
7. Profit or loss for period	0175	75.546	12.071
8. Less: interim dividend	0176		
9. Other equity instruments	0177		
A.2) ADJUSTMENTS FOR CHANGES IN VALUE	0188	(28)	(20)
1. Available-for-sale financial assets	0181		
2. Hedging transactions	0182		
3. Other	0183	(28)	(20)
A.3) GRANTS, DONATIONS AND LEGACIES RECEIVED	0194	1.029	1.367
B) NON-CURRENT LIABILITIES	0120	157.655	143.899
1. Non-current provisions	0115		
2. Non-current debt:	0116	80.503	38.557
a) Bank borrowings and debentures or other negotiable instruments	0131	70.659	31.250
b) Other financial liabilities	0132	9.844	7.307
3. Non-current debt with group and associated companies	0117	72.500	99.800
4. Deferred tax liabilities	0118	2.834	4.111
5. Other non-current liabilities	0135		
6. Non-current accruals	0119	1.818	1.431
C) CURRENT LIABILITIES	0130	268.870	231.157
Liabilities associated with non-current assets held for sale	0121		
2. Current provisions	0122	14.116	8.235
3. Current debt:	0123	17.823	8.004
a) Bank borrowings and debentures or other negotiable instruments	0133	16.280	6.495
b) Other financial liabilities	0134	1.543	1.509
4. Current debt with group and associated companies	0129	18.578	2.216
5. Trade and other payables:	0124	217.989	212.378
a) Trade payables	0125	207.243	197.095
b) Other payables	0126	8.875	10.106
c) Current tax liabilities	0127	1.871	5.177
6. Other current liabilities	0136		
7. Current accruals	0128	364	324
TOTAL EQUITY AND LIABILITIES (A + B + C)	0200	486.809	464.378



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

2. INDIVIDUAL INCOME STATEMENT (PREPARED USING THE NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

		CURRENT PERIOD (2nd HALF)	PREVIOUS PERIOD (2nd HALF)	ACCUMULATED PERIOD 31/12/2024	ACCUMULATED PREVIOUS PERIOD 31/12/2023
(+) Net revenue	0205	259.527	259.880	566.634	575.661
(+/-) Change in inventories of finished products and work in progress	0206	9.356	11.136	(18.789)	10.567
(+) Work performed by the company on its assets	0207	-			
(-) Supplies	0208	(200.103)	(210.533)	(406.840)	(454.079)
(+) Other operating income	0209	9.266	6.056	15.415	10.284
(-) Employee benefit expenses	0217	(26.794)	(23.872)	(50.949)	(46.690)
(-) Other operating expenses	0210	(44.376)	(40.088)	(82.923)	(75.765)
(-) Amortization and depreciation charges	0211	(4.692)	(4.863)	(9.408)	(10.226)
(+) Allocation of grants for non-financial assets and other	0212	217	183	330	192
(+) Excess provisions	0213	-		-	
(+/-) Impairment and gains/(losses) on disposal of intangible assets and property, plant & equipment	0214	10	(67)	31	(72)
(+/-) Other gains/(losses)	0215	-			
= OPERATING PROFIT/(LOSS)	0245	2.411	(2.168)	13.501	9.872
(+) Finance income	0250	26.010	622	65.566	1.423
(-) Finance expenses	0251	(3.111)	(1.264)	(5.043)	(2.205)
(+/-) Change in fair value of financial instruments	0252	(67)	(47)	-	28
(+/-) Exchange rate differences	0254	34	(204)	25	(104)
(+/-) Impairment and gains/(losses) on disposal of financial instruments	0255	(190)	1.097	(190)	1.097
= FINANCE PROFIT/(LOSS)	0256	22.676	204	60.358	239
= PROFIT/(LOSS) BEFORE TAX	0265	25.087	(1.964)	73.859	10.111
(+/-) Corporate income tax	0270	1.766	1.560	1.687	1.960
= PROFIT/(LOSS) FOR PERIOD ON CONTINUING OPERATIONS	0280	26.853	(404)	75.546	12.071
(+/-) Profit/(loss) for perid on discontinued operations, net of tax	0285	-			
= PROFIT/(LOSS) FOR PERIOD	0300	26.853	(404)	75.546	12.071

EARNINGS PER SHARE		Amount (X.XX euros)	Amount (X.XX euros)	Amount (X.XX euros)	Amount (X.XX euros)	
Basic	0290	0,53	0,00	1,48	0,23	
Diluted	0295		_			



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

3. INDIVIDUAL STATEMENT OF CHANGES IN EQUITY

A. INDIVIDUAL STATEMENT OF RECOGNIZED INCOME AND EXPENSES (PREPARED USING THE NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

		CURRENT PERIOD 31/12/2024	PREVIOUS PERIOD 31/12/2023
A) PROFIT/(LOSS) FOR PERIOD (from Income Statement)	0305	75.546	12.071
B) INCOME OR EXPENSES CREDITED OR CHARGED DIRECTLY TO EQUITY:	0310	329	23
Measurement of financial instruments	0320	-	-
a) Available-for-sale financial assets	0321		
b) Other income /(expenses)	0323		
2. Cash flow hedges	0330		
3. Grants, donations and legacies received	0340	449	78
4. Actuarial gains and losses and other adjustments	0344		
5. Other income or expenses credited or charged directly to equity	0343	(8)	(35)
6. Tax effect	0345	(112)	(20)
C) TRANSFERS TO PROFIT AND LOSS:	0350	(675)	(382)
Measurement of financial instruments	0355	-	3
a) Available-for-sale financial assets	0356		3
b) Other income /(expenses)	0358		
2. Cash flow hedges	0360		
3. Grants, donations and legacies received	0366	(900)	(514)
4. Other income or expenses credited or charged directly to equity	0365		
5. Tax effect	0370	225	129
TOTAL RECOGNIZED INCOME/(EXPENSES) (A+B+C)	0400	75.200	11.712



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

3. INDIVIDUAL STATEMENT OF CHANGES IN EQUITY

B. INDIVIDUAL STATEMENT OF CHANGES IN TOTAL EQUITY (1/2) (PREPARED USING THE NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

Units: thousands of euros									
			Equi						
CURRENT PERIOD		Share capital	Share premium and reserves	Treasury stock	Profit/ (loss) for the period	Other equity instruments	Adjust- ments for changes in value	Grants, donations and legacies received	Total equity
Closing balance at 01/01/2024	3010	3.241	180.339	(107.676)	12.071	-	(20)	1.367	89.322
Adjustments for changes in accounting policies	3011								
Adjustments for errors	3012								
Adjusted opening balance	3015	3.241	180.339	(107.676)	12.071	-	(20)	1.367	89.322
I. Total recognized income/(expenses)	3020				75.546		(8)	(338)	75.200
II. Transactions with shareholders or owners	3025	(167)	(149.751)	102.131	(56.451)	-	-	-	(104.238)
Capital increases/(reductions)	3026	(167)	(152.296)	152.463					-
Conversion of financial liabilities to equity	3027								-
Distribution of dividends	3028				(56.451)				(56.451)
4. Treasury stock transactions (net)	3029		2.545	(50.332)					(47.787)
5.Increases/(reductions) due to business combinations	3030								-
Other transactions with shareholders or owners	3032								-
III. Other equity transactions	3035	-	(44.380)	-	44.380	-	-	-	-
Payments based on equity instruments	3036								-
2. Transfers between equity items	3037		(44.380)		44.380				-
3. Other changes	3038								-
Closing balance at 31/12/2024	3040	3.074	(13.792)	(5.545)	75.546	-	(28)	1.029	60.284



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

3. INDIVIDUAL STATEMENT OF CHANGES IN EQUITY

B. INDIVIDUAL STATEMENT OF CHANGES IN TOTAL EQUITY (2/2) (PREPARED USING THE NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

Units: thousands of eu	iros I								
				Equity					
PREVIOUS PERIOD		Share capital	Share premium and reserves	Treasury stock	Profit/ (loss) for the period	Other equity instrume nts	Adjustment s for changes in value	Grants, donations and legacies received	Total equity
Closing balance at 01/01/2023 (comparative period)	3050	3.241	211.590	(27.561)	39.116		12	1.694	228.092
Adjustments for changes in accounting policies	3051								
Adjustments for errors	3052								
Adjusted opening balance (comparative period)	3055	3.241	211.590	(27.561)	39.116		12	1.694	228.092
I. Total recognized income/(expenses)	3060				12.071		(32)	(327)	11.712
II. Transactions with shareholders or owners	3065	-	(1.146)	(80.115)	(69.049)				(150.310)
Capital increases/(reductions)	3066								-
Conversion of financial liabilities to equity	3067								
Distribution of dividends	3068				(69.049)				(69.049)
Treasury stock transactions (net)	3069		(1.146)	(80.115)					(81.261)
5.Increases/ (reductions) due to business combinations	3070								
Other transactions with shareholders or owners	3072			-					
III. Other equity transactions	3075		(30.105)		29.933		-		(172)
Payments based on equity instruments Transfers between	3076								
Transfers between equity items	3077		(29.933)		29.933				
3. Other changes	3078		(172)						(172)
Closing balance at 31/12/2023 (comparative period)	3080	3.241	180.339	(107.676)	12.071		(20)	1.367	89.322



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

4. INDIVIDUAL STATEMENT OF CASH FLOWS (PREPARED USING NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

		CURRENT PERIOD 31/12/2024	PREVIOUS PERIOD 31/12/2023
A) CASH FLOWS FROM OPERATING ACTIVITIES (1+2+3+4)	0435	53.437	54.204
1.Profit/(loss) before tax	0405	73.859	10.111
2. Adjustments to profit/(loss)	0410	(44.619)	14.635
(+) Amortization and depreciation of intangible assets and property, plant and equipment	0411	9.408	10.226
(+/-) Other adjustments to profit/(loss) (net)	0412	(54.027)	4.409
3. Changes in working capital	0415	66.655	69.389
4. Other cash flows from operating activities:	0420	(42.458)	(39.931)
(-) Payment of interest	0421		
(+) Proceeds from dividends	0422		
(+) Proceeds from interest	0423		
(+/-) Proceeds from/(payments for) corporate income tax	0430	(43.251)	(40.186)
(+/-) Other proceeds from/(payments for) operating activities	0425	793	255
B) CASH FLOWS FROM INVESTING ACTIVITIES (1+2)	0460	(28.052)	49.755
1. Payments of investments:	0440	(32.034)	(8.876)
(-) Group companies, associates and business units	0441	(25.997)	(2.890)
(-) Property, plant and equipment, intangible assets and investment property	0442	(6.037)	(5.986)
(-) Other financial assets	0443		
(-) Non-current assets and liabilities classified as held for sale	0459		
(-) Other assets	0444		
2. Proceeds from disinvestments	0450	3.982	58.631
(+) Group companies, associates and business units	0451	3.772	57.929
(+) Property, plant and equipment, intangible assets and investment property	0452	18	97
(+) Other financial assets	0453	81	82
(+) Non-current assets and liabilities classified as held for sale	0461		
(+) Other assets	0454	111	523
C) CASH FLOWS FROM FINANCING ACTIVITIES (1+2+3)	0490	(21.851)	(158.149)
1. Proceeds from and (payments for) equity instruments:	0470	(47.787)	(81.261)
(+) Issue	0471		
(-) Amortization	0472		
(-) Acquisition	0473	(89.708)	(133.900)
(+) Disposal	0474	41.921	52.639
(+) Grants, donations and legacies received	0475		
2. Proceeds from and (payments for) financial liability instruments:	0480	82.387	(7.839)
(+) Issue	0481	131.035	20.534
(-) Repayment and amortization	0482	(48.648)	(28.373)
3. Payment of dividends and remuneration of other equity instruments	0485	(56.451)	(69.049)
D) EFFECT OF EXCHANGE RATE CHANGES	0492		
E) NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS (A+B+C+	0495	3.534	(54.190)
F) CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	0499	13.023	67.213
G) CASH AND CASH EQUIVALENTS AT END OF PERIOD (E+F)	0500	16.557	13.023

COMPONENTS OF CASH AND CASH EQUIVALENTS AT END OF PERIOD		CURRENT PERIOD 31/12/2024	PREVIOUS PERIOD 31/12/2023
(+) Cash in hand and at bank	0550	16.557	13.023
(+) Other financial assets	0552		
(-) Less: bank overdrafts repayable on demand	0553		
TOTAL CASH AND CASH EQUIVALENTS AT END OF PERIOD	0600	16.557	13.023



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION 5. CONSOLIDATED STATEMENT OF FINANCIAL POSITION (UNDER IFRS ADOPTED) (1/2)

ASSETS		CURRENT PERIOD 31/12/2024	PREVIOUS PERIOD 31/12/2023
A) NON-CURRENT ASSETS	1040	342.416	290.553
1. Intangible assets:	1030	33.950	33.902
a) Goodwill	1031		
b) Other intangible assets	1032	33.950	33.902
2. Property, plant and equipment	1033	286.622	253.652
3. Investment property	1034		
4. Investments in group and associated companies accounted for using the equity method	1035	19.516	567
5. Non-current financial investments	1036	-	24
a) At fair value through profit or loss	1047		
Of which, "Designated upon initial recognition"	1041		
b) At fair value through other comprehensive income	1042	-	-
Of which, "Designated upon initial recognition"	1043	1	-
c) At amortised cost	1044	-	24
6. Non-current derivatives	1039	-	
a) Hedging instruments	1045		
b) Other	1046		
7. Deferred tax assets	1037	2.263	2.343
8. Other non-current assets	1038	65	65
B) CURRENT ASSETS	1085	489.606	509.331
1. Non-current assets held for sale	1050		
2. Inventories	1055	329.954	337.968
3. Trade and other receivables	1060	129.552	143.314
a) Trade receivables for sale of goods and services	1061	114.827	124.550
b) Other receivables	1062	14.644	18.764
c) Current tax assets	1063	81	
4. Current financial assets	1070	227	
a) At fair value through profit or loss	1080		
Of which, "Designated upon initial recognition"	1081		
b) At fair value through other comprehensive income	1082		
Of which, "Designated upon initial recognition"	1083		
c) At amortised cost	1084	227	
5.Current derivatives	1076		
a) Hedging instruments	1077		
b) Other	1078		
6. Other current assets	1075	2.687	2.727
7. Cash and cash equivalents	1072	27.186	25.322
TOTAL ASSETS (A+B)	1100	832.022	799.884



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION 5. CONSOLIDATED STATEMENT OF FINANCIAL POSITION (UNDER IFRS ADOPTED) (2/2)

Units: thousands of euros LIABILITIES AND EQUITY		CURRENT PERIOD 31/12/2024	PREVIOUS PERIOD 31/12/2023
A) EQUITY (A.1 + A.2 + A.3)	1195	581.540	543.494
A.1) EQUITY	1180	572.051	539.408
1. Capital:	1171	3.074	3.241
a) Authorized capital	1161	3.074	3.241
b) Less: uncalled capital	1162		
2. Share premium	1172	87.636	87.636
3. Reserves	1173	673	673
4. Less treasury stock	1174	(5.545)	(107.676)
5. Retained earnings	1178	349.332	385.199
6. Other shareholder contributions	1179		
7. Profit or loss for period	1175	136.881	170.335
8. Less: interim dividend	1176		
9. Other equity instruments	1177		
A.2) ACCUMULATED OTHER COMPREHENSIVE INCOME	1188	(23)	(21)
Items not reclassified to profit and loss for the period	1186	-	
a) Equity instruments held at fair value through other comprehensive income	1185		
b) Other	1190		
2. Items that may be reclassified to profit and loss for the period	1187	(23)	(21)
a) Hedging transactions	1182		
b) Hedging differences	1184		
c) Share in other comprehensive income of joint ventures and other	1192		
d) Debt instruments held at fair value through other comprehensive income	1191		
e) Other	1183	(23)	(21)
EQUITY ATTRIBUTED TO PARENT COMPANY (A.1 + A.2)	1189	572.028	539.387
A.3) NON-CONTROLLING INTERESTS	1193	9.512	4.107
B) NON-CURRENT ASSETS	1120	93.831	56.547
1. Grants	1117		
2. Non-current provisions	1115		
3. Non-current financial liabilities:	1116	90.719	52.242
a) Bank borrowings and debentures or other negotiable securities	1131	70.659	31.250
b) Other financial liabilities	1132	20.060	20.992
4. Deferred tax liabilities	1118	366	1.515
5. Non-current derivatives	1140		
a) Hedging instruments	1141		
b) Other	1142		
6. Other non-current liabilities	1135	2.746	2.790
C) CURRENT LIABILITIES	1130	156.651	199.843
Liabilities related to current assets held for sale	1121		
2. Current provisions	1122		
3. Current finanacial liabilities:	1123	23.691	13.185
a) Bank borrowings and debentures or other negotiable securities	1133	16.280	6.495
b) Other financial liabilities	1134	7.411	6.690
4. Trade and other payables:	1124	127.712	147.150
a) Trade payables	1125	86.851	107.593
b) Other payables	1126	38.477	34.302
c) Current tax liabilities	1127	2.384	5.255
5. Current derivatives	1145		
a) Hedging instruments	1146		
b) Other	1147		
5. Other current liabilities	1136	5.248	39.508
TOTAL EQUITY AND LIABILITIES (A + B + C)	1200	832.022	799.884



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION 6. CONSOLIDATED INCOME STATEMENT (UNDER IFRS ADOPTED)

Units: thousands of euros		CURRENT PERIOD (2nd HALF)	PREVIOUS PERIOD (2nd HALF)	ACCUMULATED PERIOD 31/12/2024	ACCUMULATED PREVIOUS PERIOD 31/12/2023
(+) Net revenue	1205	434.413	448.664	763.749	829.509
(+/-) Change in inventories of finished products and work in progress	1206	(13.511)	(619)	57.851	18.552
(+) Work performed by the company on its assets	1207	86	1.905	648	3.865
(-) Supplies	1208	(138.627)	(175.127)	(343.902)	(359.641)
(+) Other operating income	1209	-	,	-	(/
(-) Employee benefit expenses	1217	(70.788)	(63.711)	(135.659)	(122.807)
(-) Other operating expenses	1210	(74.573)	(64.208)	(135.967)	(125.674)
(-) Amortization and depreciation charges	1211	(14.569)	(12.466)	(28.015)	(24.331)
(+) Allocation of grants for non-financial assets and other	1212	636	609	840	781
(+/-) Impairment of intangible assets and property, plant & lequipment	1214		000	0.0	
(+/-) Gains/(losses) on disposal of intangible assets and property, plant & equipment	1216				
(+/-) Other gains/(losses)	1215				
= OPERATING PROFIT/(LOSS)	1245	123.067	135.047	179.545	220,254
(+) Finance income	1250	159	738	259	1.504
a) Interest income calculated using the effective interest rate method	1262	(74)	(759)	26	7
b) Other	1263	233	1.497	233	1.497
(-) Finance expenses	1251	(1.706)	(582)	(2.350)	(948)
(+/-) Change in fair value of financial instruments	1252	(67)	(44)	(2.000)	28
(+/-) Gains/(losses) due to the reclassification of financial	1202	(01)	(/		20
assets held at amortised cost to financial assets held at fair	1258				
(+/-) Gains/(losses) due to the reclasification of financial assets held at fair value through other comprehensive income to financial assets held at fair value	1259				
(+/-) Exchange rate differences	1254	133	(252)	296	(86)
(+/-) Impairment on disposal of financial instruments	1255				
(+/-) Gains/(losses) on disposal of financial instruments	1257	81	(219)	81	(219)
a) Financial instruments at amortised cost	1260				
b) Rest of financial instruments	1261	81	(219)	81	(219)
= FINANCE PROFIT/(LOSS)	1256	(1.400)	(359)	(1.714)	279
(+/-) Profit/(loss) of entities measured using the equity method	1253	(119)	(112)	(141)	(125)
= PROFIT/(LOSS) BEFORE TAX	1265	121.548	134.576	177.690	220.408
(+/-) Corporate income tax	1270	(29.010)	(30.921)	(40.814)	(50.109)
= PROFIT/(LOSS) FOR PERIOD FROM CONTINUING OPERATIONS	1280	92.538	103.655	136.876	170.299
(+/-)Profit/(loss) for period from discontinued operations, net of taxes	1285				
= CONSOLIDATED PROFIT/(LOSS) FOR PERIOD	1288	92.538	103.655	136.876	170.299
a) Profit/(loss) attributed to parent company	1300	92.536	103.689	136.881	170.335
b) Profit/(loss) attributed to non-controlling interests	1289	2	(34)	(5)	(36)

	EARNINGS PER SHARE		AMOUNT (X.XX euros)	AMOUNT (X.XX euros)	AMOUNT (X.XX euros)	AMOUNT (X.XX euros)
ĺ	Basic	1290	1,81	1,95	2,67	3,20
ĺ	Diluted	1295				



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

7. CONSOLIDATED STATEMENT OF RECOGNIZED INCOME AND EXPENSES (UNDER IFRS ADOPTED)

Units: thousands of euros		CURRENT PERIOD (2nd HALF)	PREVIOUS PERIOD (2nd HALF)	CURRENT PERIOD 31/12/2024	PREVIOUS PERIOD 31/12/2023
A) PROFIT/(LOSS) FOR PERIOD (from Income Statement)	1305	92.538	103.655	136.876	170.299
B) OTHER COMPREHENSIVE INCOME - ITEMS NOT					
RECLASSIFIED TO PROFIT AND LOSS FOR THE PERIOD	1310				
Remeasurement (reversal of remeasurement) of property, plant					
and equipment and intangible assets	1311				
2. Actuarial gains and losses	1344				
3. Share in other recognized comprehensive income from					
investments in joint ventures and associates	1342				
4. Equity instruments held at fair value through other	1346				
5. Other income and expenses not reclassified to profit and loss for					
the period	1343				
6. Tax effect	1345				
SUBSEQUENTLY BE RECLASSFIED TO PROFIT AND LOSS FOR THE PERIOD:	1350	6	3	(2)	(13)
1. Hedging transactions:	1360				
a) Gains/(losses) on remeasurement	1361				
b) Amounts transferred to profit and loss	1362				
c) Amounts transferred at initial value of hedged items	1363				
d) Other reclassifications	1364				
2. Conversion differences:	1365	6	3	-2	-18
a) Gains/(losses) on remeasurement	1366	6	3	-2	-18
b) Amounts transferred to profit and loss	1367				
c) Other reclassifications	1368				
3. Share in other recognized comprehensive income from					
investments in joint ventures and associates	1370				
a) Gains/(losses) from measurement	1371				
b) Amounts transferred to profit and loss	1372				
c) Other reclassifications	1373				
4. Debt instruments held at fair value through other comprehensive income:	1381				
a) Gains/(losses) on remeasurement	1382				
b) Amounts transferred to profit and loss	1383				
c) Other reclassifications	1384				
Other comprehensive income and expenses that may subsequently be reclassified to profit and loss for the period:	1375	-	-	-	7
a) Gains/(losses) on remeasurement	1376	-	-	-	7
b) Amounts transferred to profit and loss	1377				
c) Other reclassifications	1978				
6. Tax effect	1380				-2
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (A+B+C)	1400	92.544	103.658	136.874	170.286
a) Attributed to parent company	1398	92.542	103.692	136.879	170.322
b) Attributed to non-controlling interests	1399	2		-5	-36

This English version has been translated by the entity itself at its sole responsibility and cannot be considered to be official.



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

8. CONSOLIDATED STATEMENT OF CHANGES IN TOTAL EQUITY (UNDER IFRS ADOPTED) (1/2)

			Equi	ty attribute	d to parent co	mpany				
				Equity						
CURRENT PERIOD		Share capital	Share premium and reserves	Treasury stock	Profit/ (loss) for the per. attributed to parent company	Other equity instru- ments	Adjust- ments for changes in value	Non- controlling interests	Total equity	
Closing balance at 01/01/2024	3110	3.241	473.508	(107.676)	170.335	-	(21)	4.107	543.494	
Adjustments for changes in accounting policies	3111									
Adjustments for errors	3112									
Adjusted opening balance	3115	3.241	473.508	(107.676)	170.335	•	(21)	4.107	543.494	
I. Total recognized income/(expenses)	3120				136.881		(2)	(5)	136.874	
II. Transactions with shareholders or owners	3125	(167)	(149.751)	102.131	(56.451)	-	-	5.410	(98.828)	
1. Capital increases/(reductions)	3126	(167)	(152.296)	152.463					-	
Conversion of financial liabilities to equity	3127								-	
3. Distribution of dividends	3128				(56.451)				(56.451)	
Treasury stock transactions (net)	3129		2.545	(50.332)					(47.787)	
5.Increases/(reductions) due to business combinations	3130								-	
6. Other transactions with shareholders or owners	3132							5.410	5.410	
III. Other equity transactions	3135	-	113.884	-	(113.884)	-	-	-	_	
Payments based on equity instruments	3136								-	
2. Transfers between equity items	3137		113.884		(113.884)					
3. Other changes	3138								-	
Closing balance at 31/12/2024	3140	3.074	437.641	(5.545)	136.881	-	(23)	9.512	581.540	



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

8. CONSOLIDATED STATEMENT OF CHANGES IN TOTAL EQUITY (UNDER IFRS ADOPTED) (2/2)

			Equit	y attributed	to parent c	ompany			
				Equity					
PREVIOUS PERIOD		Share capital	Share premium and reserves	Treasury stock	Profit/ (loss) for the per. attributed to parent company	Other equity instru- ments	Adjust- ments for changes in value	Non- controlling interests	Total equity
Closing balance at									
01/01/2023 (comparative	3150	3.241	344.671	(27.561)	199.669		(8)	1.367	521.379
period)									
Adjustments for changes in	3151								
accounting policies									
Adjustments for errors	3152	0.044	0.44.074	(07.504)	100.000		(0)	4.007	504.070
Adjusted opening balance	3155	3.241	344.671	(27.561)	199.669		(8)	1.367	521.379
I. Total recognized	3160				170.335		(13)	(36)	170.286
income/(expenses)							` '	, ,	
II. Transactions with	3165	-	(1.146)	(80.115)	(69.049)			2.776	(147.534)
shareholders or owners			` ,	, ,	` ′				, ,
1. Capital	3166								-
increases/(reductions) 2. Conversion of financial									
	3167								
liabilities to equity 3. Distribution of dividends	3168				(69.049)				(69.049)
Treasury stock transactions					(,				
(net)	3169		(1.146)	(80.115)					(81.261)
5.Increases/(reductions) due									
to business combinations	3170								
6. Other transactions with	0470							0.770	0.770
shareholders or owners	3172							2.776	2.776
III. Other equity	2475		400.000		(400,000)				(007)
transactions	3175		129.983		(130.620)		_		(637)
1. Payments based on equity	3176								
instruments	3176								
2. Transfers between equity	3177		130.620		(130.620)				
items					(100.020)				
3. Other changes	3178		(637)						(637)
Closing balance at									
31/12/2023 (comparative	3180	3.241	473.508	(107.676)	170.335		(21)	4.107	543.494
period)									



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION 9.A. CONSOLIDATED STATEMENT OF CASH FLOWS (INDIRECT METHOD) (UNDER IFRS ADOPTED)

Units: thousands of euros		CURRENT PERIOD 31/12/2024	PREVIOUS PERIOD 31/12/2023
A) CASH FLOWS FROM OPERATING ACTIVITIES (1 + 2 + 3 + 4)	1435	138.278	113.247
1.Profit/(loss) before tax	1405	177.690	220.408
2. Adjustments to profit/(loss)	1410	28.941	26.290
(+) Amortization and depreciation of intangible assets and property, plant and equipment	1411	28.015	24.331
(+/-) Other adjustments to profit/(loss) (net)	1412	926	1.959
3. Changes in working capital	1415	8.960	(34.448)
4. Other cash flows from operating activities:	1420	(77.313)	(99.003)
(-) Payment of interest	1421		
(-) Payment of dividends and remuneration of other equity instruments	1430		
(+) Proceeds from dividends	1422		
(+) Proceeds from interest	1423	-	-
(+/-) Proceeds from/(payments of) corporate income tax	1424	(44.230)	(40.856)
(+/-) Other proceeds from/(payments for) operating activities	1425	(33.083)	(58.147)
B) CASH FLOWS FROM INVESTING ACTIVITIES (1+2+3)	1460	(81.058)	(52.028)
1. Payments of investments:	1440	(81.309)	(55.787)
(-) Group companies, associates and business units	1441	(19.090)	(600)
(-) Property, plant and equipment, intangible assets and investment property	1442	(62.219)	(55.187)
(-) Other financial assets	1443	-	-
(-) Non-current assets and liabilities classified as held for sale	1459		
(-) Other assets	1444		
2. Proceeds from disinvestments	1450	117	2.270
(+) Group companies, associates and business units	1451	-	1.800
(+) Property, plant and equipment, intangible assets and investment property	1452	37	382
(+) Other financial assets	1453	80	88
(+) Non-current assets and liabilities classified as held for sale	1461		
(+) Other assets	1454		
3. Other cash flows from investing activities	1455	134	1.489
(+) Proceeds from dividends	1456		
(+) Proceeds from interest	1457	134	1.489
(+/-) Other proceeds from/(payments for) investing activities	1458		
C) CASH FLOWS FROM FINANCING ACTIVITIES (1+2+3+4)	1490	(55.356)	(160.842)
1. Proceeds from and (payments of) equity instruments:	1470	(47.787)	(81.261)
(+) Issue	1471		
(-) Amortization	1472		
(-) Acquisition	1473	(89.708)	(133.900)
(+) Disposal	1474	41.921	52.639
2. Proceeds from/ (payments for) financial liability instruments:	1480	45.241	(12.920)
(+) Issue	1481	96.952	734
(-) Repayment and amortization	1482	(51.711)	(13.654)
3. Payment of dividends and remuneration of other equity instruments	1485	(56.451)	(69.049)
4. Other cash flows from financing activities	1486	3.641	2.388
(-) Payment of interest	1487	(1.769)	(388)
(+/-) Other proceeds from /(payments for) financing activities	1488	5.410	2.776
D) EFFECT OF CHANGES IN EXCHANGE RATES	1492		
E) NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS (A+B+C+D)	1495	1.864	(99.623)
F) CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	1499	25.322	124.945
G) CASH AND CASH EQUIVALENTS AT END OF PERIOD (E+F)	1500	27.186	25.322
· ·		CURRENT	

COMPONENTS OF CASH AND CASH EQUIVALENTS AT END OF PERIOD		CURRENT PERIOD 31/12/2024	PREVIOUS PERIOD 31/12/2023
(+) Cash in hand and at bank	1550	21.180	25.322
(+) Other financial assets	1552	6.006	
(-) Less: bank overdrafts repayable on demand	1553	·	
TOTAL CASH AND CASH EQUIVALENTS AT END OF PERIOD	1600	27.186	25.322

This English version has been translated by the entity itself at its sole responsibility and cannot be considered to be official.



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION 10. DIVIDENDS PAID

		CURRENT	Γ PERIOD	PREVIOU	S PERIOD
		Euros per share (X.XX)	Amount (thousand euros)	Euros per share (X.XX)	Amount (thousand euros)
Ordinary shares	2158	1,10	59.618	1,29	69.886
Other shares (non-voting, redeemable, etc.)	2159				
Total dividends paid	2160	1,10	59.618	1,29	69.886
a) Dividends charged to profit and loss	2155	0,22	12.071	0,72	39.116
a) Dividends charged to reserves or share premium	2156	0,88	47.547	0,57	30.770
c) Dividends in kind	2157				
d) Flexible payment	2154				

This English version has been translated by the entity itself at its sole responsibility and cannot be considered to be official.



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION 11. SEGMENT REPORTING

Units: thousands of euros

Table 1:

Table 1:							
GEOGRAPHICAL AREA	Distribution of net revenue by geographical area INDIVIDUAL CONSOLIDATED						
		CURRENT PERIOD	RRENT PERIOD PREVIOUS PERIOD CURRENT PERIOD PREVIOUS				
Domestic market	2210	435.176	423.577	277.011	273.355		
Exports:	2215	131.458	152.084	486.738	556.154		
a) European Union	2216	75.934	79.496	146.107	143.645		
Eurozone	2217	74.626	77.067	142.511	140.392		
Non Eurozone	2218	1.308	2.429	3.596	3.253		
c) Other countries	2219	55.524	72.588	340.631	412.509		
TOTAL	2220	566.634	575.661	763.749	829.509		

Table 2:

			CONSO	LIDATED		
			ue from external omers	Profit or loss		
SEGMENTS		CURRENT PERIOD	PREVIOUS PERIOD	CURRENT PERIOD	PREVIOUS PERIOD	
Manufacturing	2221	600.351	644.407	170.352	187.406	
Marketing	2222	427.528	420.232	41.458	(21.620)	
Other	2223			(181)	(73)	
	2224					
	2225					
	2226					
	2227					
	2228					
	2229					
(-)Adjustments between segments	2230	(264.130)	(235.130)	(74.753)	4.586	
TOTAL	2235	763.749	829.509	136.876	170.299	



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION 12. AVERAGE NUMBER OF EMPLOYEES

	INDIV	IDUAL	CONSOL	LIDATED	
		CURRENT PERIOD	PREVIOUS PERIOD	CURRENT PERIOD	PREVIOUS PERIOD
AVERAGE NUMBER OF EMPLOYEES	2295	693	686	2.179	2.096
Men	2296	290	288	1.009	963
Women	2297	403	398	1.170	1.133

IV. SELECTED FINANCIAL INFORMATION 13. COMPENSATION RECEIVED BY DIRECTORS AND SENIOR MANAGEMENT

DIRECTORS:

		Amount (the	usand euros)
Item of compensation:		CURRENT PERIOD	PREVIOUS PERIOD
Remuneration for membership of Board or Board committees	2310	660	660
Salaries	2311	1.416	1.238
Variable cash remuneration	2312	1.189	868
Share-based remuneration systems	2313		
Indemnities	2314		
Long-term savings systems	2315	6	6
Other	2316		
TOTAL	2320	3.271	2.772

		Amount (tho	usand euros)
SENIOR MANAGEMENT:		CURRENT	PREVIOUS
		PERIOD	PERIOD
Total compensation received by senior management	2325	2.649	1.926



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION 14. RELATED-PARTY TRANSACTIONS AND BALANCES (1/2)

onts. tribusarius or curos		CURRENT PERIOD				
EXPENSES AND INCOME		Significant share- holders	Directors and senior manage- ment	Persons, companies or entities belonging to the group		Total
1) Finance expenses	2340					
2) Rentals	2343		18		2.739	2.757
3) Services received	2344					
4) Purchases of goods (finished or in progress)	2345					
5) Other expenses	2348					
EXPENSES (1+2+3+4+5)	2350	0	18	0	2.739	2.757
6) Finance income	2351					
7) Dividends received	2354					
8) Services provided	2356				100	100
9) Sale of goods (finished or in progress)	2357					
10) Other income	2359					
INCOME (6+7+8+9+10)	2360	0	0	0	100	100

		CURRENT PERIOD				
OTHER TRANSACTIONS		Significant share- holders	Directors and senior manage- ment	Persons, companies or entities belonging to the group	Other related parties	Total
Financing agreements: loans & capital contributions (lender)	2372				19.316	19.316
Financing agreements: loans & capital contributions (borrower)	2375					
Guarantees and guarantee deposits furnished	2381					
Guarantees and guarantee deposits received	2382					
Commitments acquired	2383					
Dividends and other profits distributed	2386	36.735				36.735
Other transactions	2385					

		CURRENT PERIOD				
BALANCES AT END OF PERIOD		Significant share- holders	Directors and senior manage- ment	Persons, companies or entities belonging to the group	Other related parties	Total
1) Customers and trade debtors	2341				30	30
Loans and credits granted	2342				227	227
3) Other amounts receivable	2346					
TOTAL BALANCES RECEIVABLE (1+2+3)	2347				257	257
4) Suppliers and trade creditors	2352				157	157
5) Loans and credits received	2353					
6) Other payment obligations	2355		2.920			2.920
OTHER BALANCES PAYABLE (4+5+6)	2358	0	2.920	0	157	3.077



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION 14. RELATED-PARTY TRANSACTIONS AND BALANCES (2/2)

RELATED-PARTY TRANSACTIONS		PREVIOUS PERIOD				
EXPENSES AND INCOME		Significant share- holders	Directors and senior manage- ment	Persons, companies or entities belonging to the group	Other related parties	Total
1) Finance expenses	6340					
2) Rentals	6343		25		2.676	2.701
3) Services received	6344					
4) Purchases of goods (finished or in progress)	6345					
5) Other expenses	6348					
EXPENSES (1+2+3+4+5)	6350		25		2.676	2.701
6) Finance income	6351					
7) Dividends received	6354					
8) Services provided	6356				25	25
9) Sale of goods (finished or in progress)	6357					
10) Other income	6359					
INCOME (6+7+8+9+10)	6360				25	25

		PREVIOUS PERIOD				
OTHER TRANSACTIONS		Significant share- holders	Directors and senior manage- ment	Persons, companies or entities belonging to the group	Other related parties	Total
Financing agreements: loans & capital contributions (lender)	6372				600	600
Financing agreements: loans & capital contributions (borrower)	6375					
Guarantees and guarantee deposits furnished	6381					
Guarantees and guarantee deposits received	6382					
Commitments acquired	6383				900	900
Dividends and other profits distributed	6386	43.488				43.488
Other transactions	6385					

		PREVIOUS PERIOD				
BALANCES AT END OF PERIOD		Significant share- holders	Directors and senior manage- ment	Persons, companies or entities belonging to the group	Other related parties	Total
Customers and trade debtors	6341					
2) Loans and credits granted	6342					
3) Other amounts receivable	6346				10	10
TOTAL BALANCES RECEIVABLE (1+2+3)	6347				10	10
4) Suppliers and trade creditors	6352				206	206
5) Loans and credits received	6353				·	
6) Other payment obligations	6355		2.093			2.093
OTHER BALANCES PAYABLE (4+5+6)	6358		2.093		206	2.299